A split-face comparison found no difference between onabotulinumtoxinA and prabotulinumtoxinA for the treatment of glabellar frown lines, according to a study presented at the Women in Ophthalmology Summer Symposium.
“We sought to evaluate the difference in efficacy and safety of onabotulinumtoxinA, an FDA-approved neuromuscular blocking agent that is widely used for cosmetic rejuvenation of the face, and prabotulinumtoxinA, an FDA-approved novel neurotoxin with a similar mechanism of action in treating glabellar lines,” Preeya Mehta, MD, said in her presentation. “At the